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Background: Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE)
is a randomized controlled trial that follows a novel multi-arm, multi-stage (MAMS) design. We describe
methodological and practical issues arising with (1) stopping recruitment to research arms following a pre-planned
intermediate analysis and (2) adding a new research arm during the trial.
Methods: STAMPEDE recruits men who have locally advanced or metastatic prostate cancer who are starting
standard long-term hormone therapy. Originally there were five research and one control arms, each undergoing a
pilot stage (focus: safety, feasibility), three intermediate ‘activity’ stages (focus: failure-free survival), and a final
‘efficacy’ stage (focus: overall survival). Lack-of-sufficient-activity guidelines support the pairwise interim comparisons
of each research arm against the control arm; these pre-defined activity cut-off becomes increasingly stringent over
the stages. Accrual of further patients continues to the control arm and to those research arms showing activity
and an acceptable safety profile. The design facilitates adding new research arms should sufficiently interesting
agents emerge. These new arms are compared only to contemporaneously recruited control arm patients using the
same intermediate guidelines in a time-delayed manner. The addition of new research arms is subject to adequate
recruitment rates to support the overall trial aims.
Results: (1) Stopping Existing Therapy: After the second intermediate activity analysis, recruitment was discontinued
to two research arms for lack-of-sufficient activity. Detailed preparations meant that changes were implemented
swiftly at 100 international centers and recruitment continued seamlessly into Activity Stage III with 3 remaining
research arms and the control arm. Further regulatory and ethical approvals were not required because this was
already included in the initial trial design.
(2) Adding New Therapy: An application to add a new research arm was approved by the funder, (who also
organized peer review), industrial partner and regulatory and ethical bodies. This was all done in advance of any
decision to stop current therapies.
Conclusions: The STAMPEDE experience shows that recruitment to a MAMS trial and mid-flow changes its design
are achievable with good planning. This benefits patients and the scientific community as research treatments are
evaluated in a more efficient and cost-effective manner.
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Randomized controlled trialBackground
Multi-arm multi-stage trials
Adaptive clinical trials are increasingly discussed and pre-
sented. The multi-arm, multi-stage (MAMS) design [1,2]
is one example of a flexible, seamless phase II/III rando-
mized controlled trial. Detail on the general rationale for
the MAMS design has been published elsewhere [3], but
in brief, this approach allows for several research
approaches to be assessed simultaneously against a com-
mon control group. Accrual resources are directed away
from arms that show either insufficient activity on an
intermediate primary outcome measure or unacceptable
toxicity so that recruitment becomes increasingly focused
towards the more promising research arms and the con-
trol arm. The MAMS design provides an efficient method
for acquiring multi-agent prospective randomized data
synchronously, requiring less time and needing fewer
patients while simultaneously reducing the trial bureau-
cracy that is associated with a program of separate Phase
II and Phase III trials. The MAMS approach thereby
increases the likelihood of identifying one or more suc-
cessful treatments in a single trial. It also decreases the
likelihood of the whole trial stopping prematurely because
the chance of multiple treatment approaches being insuffi-
ciently tolerated or ineffective is reduced.2005 2006 2007 2008 2009 2010 2011
ADT-aloneA
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Figure 1 Trial arms open to allocation and further timelines at start oThe ability to add new research arms is an added advan-
tage; initiating and conducting clinical trials remains
resource-intensive and time-consuming both in terms of
securing funding and gaining regulatory approval. The
concept of adding new research arms within the context
of an ongoing trial, thereby utilizing its existing machinery
and recruitment base, is appealing. This can bring efficien-
cies in cost, personnel, and recruitment, leading to a re-
duction by many years in the time taken to initiate and
recruit to the trial. This could further allow companies a
longer period to generate profits within their patent.
The STAMPEDE trial
STAMPEDE (Systemic Therapies for Advancing or Meta-
static Prostate cancer: Evaluation of Drug Efficacy) is a
multi-center, open-label, multi-arm multi-stage rando-
mized trial. The aim is to identify new treatments that
could improve survival in men with high-risk locally
advanced or metastatic prostate cancer and who are start-
ing standard care with long-term hormone therapy (HT)
with androgen deprivation. STAMPEDE assesses many re-
search treatments, all added to standard HT: docetaxel,
zoledronic acid, celecoxib and, now, abiraterone. The
detailed clinical rationale of the trial has been presented
elsewhere [4-6]. The trial is approved by the appropriate2012 2013 2014 2015 2016 2017
f trial.
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ginal trial and the anticipated timelines; Figure 2 shows
observed accrual rates.Rationale for publication
The methodological details of STAMPEDE’s design and
the practical issues of initiating the trial have been pub-
lished elsewhere [7], but here we report on ongoing trial
logistics, discussing the early stopping of two trial arms
after an intermediate lack-of-sufficient-activity analysis
(often referred to as a ‘lack-of-benefit’ for short) and the
activation of a new research arm.Ar
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Figure 2 Cumulative accrual of patients and activation of sites.Managing early stopping following lack-of-benefit
analysis
Trial design
The multi-arm multi-stage design of STAMPEDE has a
series of formal intermediate analyses for each trial arm
that take place at the end of each intermediate activity
stage (AS); STAMPEDE has three such stages. Each re-
search arm is compared separately to the common con-
trol arm in a pairwise fashion. However, there is no
comparison of the research arms against one another at
this time. The trial’s design specifies parameters for these
intermediate analyses separately from the final analyses.
The trial is designed to detect a clinically relevantAS
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overall survival. The assumption is that any such benefit
should be preceded by a relative benefit at least as large
in the intermediate primary outcome measure - failure-
free survival (FFS). There is high power for each pairwise
comparison throughout (≥90%) the trial and the pairwise
significance level moves from permissive at the inter-
mediate stages to strict at the final stage. Activity cut-
point guidelines are derived for each intermediate
analysis using the methods of Royston et al. [1] Table 1
depicts the design parameters. These are achieved using
the n stage program, available in Stata [8,9].
The intermediate analyses are triggered when a set
number of events have been observed in the control
arm. Focusing on the control arm in this way enables
each analysis to be monitored and anticipated without
revealing data on accumulating differences (or a lack of
them) from the research arms. By considering the
observed accrual rate and accumulating event rate in the
control arm, it is possible to anticipate the time of
the next intermediate analysis with reasonable precision.
This can be calculated with the ARTPEP program (also
available in Stata) [10]. Therefore, the first step towards
planning can easily be achieved, which facilitates the
planning of when the Independent Data Monitoring
Committee (IDMC) should meet to review the data.
A large proportion of agents are unsuccessful in phase
III trials [11-13], so it can be reasonably anticipated that
accrual to at least one research arm in a MAMS trial is
likely to be stopped early. Therefore, actions can, and
should be, planned in advance of any early stopping de-
cision. The statistical design explicitly considers stopping
for lack-of-benefit, but research arms can also be
stopped for reasons of harm or toxicity. Plans for either
contingency can therefore be developed in anticipation
of either eventuality.
Advanced preparation
In the governance and oversight structure of STAM-
PEDE, the IDMC is advisory to a Trial Steering Commit-
tee (TSC), which has independent members (includingTable 1 Design parameters by trial stage for original research
Trial Stage Type Primary outcome
measure
Target hazard
ratio
1 Activity FFS 0.75
2 Activity FFS 0.75
3 Activity FFS 0.75
4 Efficacy OS 0.75
Overall - - -
1 Number of control arm events provoking analyses for the original research compa
events would be different for an equal allocation ratio.
Key: FFS = failure-free survival; OS = overall survival; HR = hazard ratio.
Note: these parameters are used for each pairwise comparison of research vs contrthe Chair) and representatives from the Trial Manage-
ment Group (TMG), the latter being the committee re-
sponsible for the day-to-day running of the trial. The
IDMC decides which accumulating data, if any, should
be seen by the TSC executive when they next meet and
also guides interpretation.
Before the first intermediate analysis, a joint meeting
of the TSC and IDMC was held in which the design of
the trial was reviewed and a number of hypothetical sce-
narios were considered, anticipating a number of differ-
ent ‘results’ at the intermediate stages. The aim was to
provoke discussion on what sort of decisions each com-
mittee might make when reviewing certain outcomes
and what information the two committees could expect
to see to make such recommendations and decisions.
A series of “what if. . .?” questions were considered
months before the first intermediate activity analysis dis-
cussions were held within the trials unit and within the
TMG about the actions and communications required
before and after each intermediate analysis.. These ques-
tions included the following: What if one arm was
stopped for safety after a given review or was stopped
for lack-of-benefit; what if more than one arm was
halted and for the same or different reasons; and even,
what if no changes were made?
Table 2 summarizes the planned actions and timelines
targeted. Communicating to trial sites that changes
might be forthcoming was started many weeks before
each intermediate analysis. The potential for stopping
recruitment to arms was built into the trial design;
therefore, such activity did not require a formal protocol
amendment. A letter was circulated to each clinical site
from the regulatory authority confirming this fact.
Many activities (Table 2) were planned to occur
quickly after a TSC decision to stop recruitment to any
arm. The planned timelines were the same for most ac-
tivities, regardless whether stopping an arm for lack-of-
benefit or toxicity; although the plans for notifying staff
internally and turning off randomisation needed to be
quicker in the instance of toxicity. The reason for this
disparity in times is because it was anticipated that armsarms
Power One-sided
Significance level
Critical HR Trigger events1
(control)
95% 0.500 1.00 114
95% 0.250 0.92 215
95% 0.100 0.89 334
90% 0.025 - 400
83% 0.013 - -
risons with a 2:1 allocation ratio in favour of control. The required number of
ol.
Table 2 Planned actions and timelines when accrual is stopped to trial arms
Action required Timelines
Safety LOB
Notify sites in writing of IDMC meeting date to pre-warn -28 d -28 d
Circulate prior letter from regulatory agency confirming that stopping early for
LOB is not a substantial amendment, but part of trial design
-28 d -28 d
IDMC meeting -7 d -7 d
IDMC notes and recommendations finalised (<1 w) (<1 w)
TSC meeting: stop / continue decision for each research arm Day 0 Day 0
Turn off randomisation to arms stopping early for safety <24 h <1 w
Notify centres by email; patients to ignore irrelevant parts of PIS <24 h <24 h
Notify relevant industry partners <24 h <24 h
Notify TMG members <24 h <24 h
Alert trials unit staff to potential queries <24 h <48 h
Phone all site PIs. Instructed to hand-amend PIS and CF. Updated documentation to follow <1 w <1 w
Protocol and documents updated and agreed by TMG <1 w <1 w
Summary information for patients <2 w <2 w
Notify ethics committee and regulatory agency (for information only) <2 w <2 w
Detailed discussions with industry partners <1 m <1 m
TMG review of processes <1 m <1 m
Key: LOB = lack-of-benefit; IDMC = Independent Data Monitoring Committee; TSC = Trial Steering Committee; TMG = Trial Management Group; PIS = patient
information sheet; CF = consent form; h = hour; w = week.
Note: the observed timelines broadly followed these plans.
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trend towards an advantage to the research arm, albeit
an insufficiently large advantage to encourage recruit-
ment of more patients to that comparison. For example,
at the third intermediate analysis, the activity cut point
is a hazard ratio of 0.89. Therefore, accrual may be
stopped to an arm with a favorable hazard ratio of 0.90.
In the absence of an overriding safety concern it was
reasonable to allow a little more time to turn off alloca-
tion to such a treatment.
Notifications to the ethics committee(s) and the regu-
lators were planned. Although no immediate protocol
amendment would be required, it was decided that the
protocol would be updated as soon as practicable after
changes to study arms to simplify activities for sites. The
Patient Information Sheets (PIS) would be updated im-
mediately with removal of information that was no
longer pertinent and sent to the ethics committee(s) for
information.Results
The IDMC has met at least annually to review accumu-
lating data. The data for the first formal intermediate ac-
tivity analysis were frozen on 09 February 2010 with
1,424 patients randomized and 129 control-arm FFS
events. The HR guideline cut point was 1.00. The review
took place on 30 March 2010 by which time 1,518patients had been randomized. The IDMC reviewed all
data on the main outcome measures and recommended
no changes.
The data for the second formal intermediate activity
analysis were frozen on 01 February 2011 with 2,043
patients randomized and 209 control arm FFS events.
The HR cut point was now 0.92. The IDMC meeting
took place on 31 Mar 2011 by which time 2,163 patients
had been randomized. The IDMC recommended that
(i) the TSC see FFS data for both arms containing cele-
coxib and (ii) that no further patients be recruited to ei-
ther celecoxib-containing arm. The detailed clinical
findings are reported elsewhere [14,15].Practical experience
The TSC met on 06 April 2011 and approved the IDMC
recommendations. They decided that (i) accrual should
stop to both celecoxib-containing arms (D and F), follow-
ing the lack-of-benefit guidelines; (ii) patients currently
receiving celecoxib should be advised to stop celecoxib;
(iii) comparative data celecoxib versus control arm (D
versus A) should be shared with investigators; and
(iv) data from the celecoxib plus zoledronic acid arm (F)
should not be released as recruitment to the other zole-
dronic acid-containing arms (B and E) was to continue.
The observed HR for celecoxib versus control was
0.98, which did not meet the cut point. Although there
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toxicity, no drugs are without potential for unwanted
side-effects, and there was insufficient evidence of bene-
fit to outweigh such risk.
As some patients were being advised to stop their
treatment, it was decided to follow the safety rather than
the lack-of-benefit timelines. By the afternoon of Day 0,
(TSC meeting day) on 06 April 2011, the allocation to
the celecoxib-containing arms in the randomization sys-
tem had been disabled. All sites were notified by email
that day and were told to re-advise patients who had
consented to the trial but who had not yet been rando-
mized. The Chief Investigator, patient representative and
trials unit also agreed to a temporary revised version of
the PIS. A quick response to this was facilitated by draft-
ing many versions of the PIS before the IDMC meeting
to reflect the needs following a number of hypothetical
outcomes. Sites were offered a new electronic version of
the revised PIS or they could manually cross out the few
newly irrelevant sections of their current version. Sites
were also told to advise patients to stop taking celecoxib
at their next routine visit but that no urgent visits by
patients to the clinic were required. A small number of
patients who had been on celecoxib for many months
chose to remain on treatment; only five patients are
reported as still being on celecoxib at the start of July
2011.
On Day 1, phone calls were made to all site principal
investigators (PIs) to ensure they were aware of and
understood the actions taken. The trial team also
worked with consumers to develop a summary of the
results and actions to give to all patients. We thought it
important for all trial patients to understand this infor-
mation, not just those patients allocated to celecoxib-
arms. This summary of results and actions was provided
to sites for distribution to patients. Finally, industrial
partners were apprised of the actions.
By Day 7, the PIS had been formally updated, submit-
ted to the main ethics committee for information and
distributed to sites. The regulatory authority was for-
mally notified at this time. The protocol was formally
amended (to version 7.0) after two months and submit-
ted in June 2011 to the regulatory authority and ethics
committee as a non-substantial amendment for informa-
tion only.
These processes ran smoothly and no problems were
reported from any of the governance bodies or from par-
ticipating sites. The most common question from a
small number of sites related to the use of new docu-
ments without apparent ‘prior’ approval. The earlier let-
ter from the regulatory agency was sufficient to respond
to these queries.
Recruitment continued to the control arm and to the
remaining three research arms at good rates, with 47patients in the 4 full weeks prior to change and 42 patients
in the subsequent 4 full weeks. Importantly, follow-up
continues for patients allocated to the celecoxib-
containing arms.
Patients recently randomized to celecoxib-containing
arms
A small number of patients randomized shortly prior to
the halting of the celecoxib-containing arms had not ne-
cessarily had a chance to start their allocated treatment.
It was agreed that patients allocated to arm D (HTplus
celecoxib) and who still met all of the eligibility criteria
for new patients joining the trial could be offered the
opportunity to withdraw from STAMPEDE and to be re-
randomized as a new patient. This was discussed with
the relevant sites and five patients of seven meeting
these criteria chose re-randomization. Since recruitment
to and treatment within arm B (zoledronic acid) was
continuing, patients on arm F (celecoxib plus zoledronic
acid) were recommended to stop their celecoxib treat-
ment and were not offered re-randomization. No patient
will contribute more than once to any comparison. Sen-
sitivity analyses will be considered.
Handling investigator assumptions
Investigators will no doubt make implicit assumptions
about any research arms that continue accrual beyond
each intermediate analysis. However, community uncer-
tainty should not be affected by unreleased data from
these intermediate comparisons. The knowledge that
there are likely encouraging data on an early outcome
measure at the intermediate analyses just reinforces the
need to continue randomization to gain stronger evi-
dence for the definitive primary outcome measure. If any
of the arms showed early results for the definitive pri-
mary outcome measure that would be sufficiently con-
vincing to influence clinical practice, the IDMC could
recommend early release of the data. The strengths and
weaknesses of that data would be discussed.
Designing new comparisons
Rationale for including new research arms
The practical reasons for choosing the five research arms
at the outset of STAMPEDE has been discussed previ-
ously [7]. The STAMPEDE TMG has now successful
activated one further research arm (G, abiraterone) and
further arms are being considered.
The motivations for including a new research arm are
many. The philosophy at the outset was to evaluate mul-
tiple agents from different classes but as new agents
emerge and potential synergies from agents within the
same class become a possibility, it is important that con-
sideration is given to testing these alone, and possibly in
combination, within the framework of a MAMS trial
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ered for addition when there are robust and convincing
scientific hypotheses.
There is huge interest in new ‘hormone therapies’ for
prostate cancer with the first such agent, abiraterone, an
androgen biosynthesis inhibitor, licensed in 2011. Drugs
approved in patients with late stage disease will generally
go on to be tested in earlier settings. The efficiencies
available in MAMS trials [3] are as relevant to new
agents as they are in the original arms. These efficiencies
include the following: (i) using one protocol to allow for
new comparisons to be introduced by amendment; (ii)
quicker recruitment to the new comparison by activating
participating sites for the new comparison more quickly
than is possible in any new, separate study; (iii) the
increased chance of allocation of a research arm, which
may appeal to many patients, thereby boosting accrual;
(iv) the contemporaneous accrual to comparisons which
overlap in time means no gaps between, and no compe-
tition between, trials; (v) phase II assessments of activity
are incorporated; and (vi) together, the duration and cost
of such a setting up a new comparison in this way would
be considerably shorter and lower than any separate,
new trial.
The rationale for considering any new research arm
would need to be clear. The STAMPEDE TMG set for-
ward a number of criteria summarized in Table 3.When to add new arms
Many new agents are being developed in prostate cancer,
often with differing mechanisms of action and demon-
strable survival advantages in the later, castrate-Table 3 Criteria for potential new research arms
• Sound rationale, including a robust biological hypothesis and
compelling evidence of activity that strongly identifies a need to assess
a research approach in the setting studied.
• Positive evidence of mechanisms or synergy of action (or both) in the
disease area
• Investigator enthusiasm for the new research arm.
• Pharmaceutical research agents would need to be licensed or be close
to being licensed at the time of activation. Without a licensed use for
the drug (usually in later disease), data in the target setting are likely to
be of limited value.
• Relevant industry partners willing to collaborate and contribute to the
trial, if the research arm is a pharmaceutical agent.
• Successful independent peer review as for a new study.
• Recruitment to new arm must not jeopardise completion of the
ongoing research arms, e.g. by diluting recruitment excessively. This
means that the accrual rate must be better than predicted in the
original trial or that other research arms have already stopped accrual
early. STAMPEDE is presently recruiting at around 700 patients/year
when 500 patients/year were targeted. This permitted capacity to
consider new research agents even while all original arms remained
open.
• The new comparison must still be relevant when it matures.refractory stages of the disease. These include
approaches based on cytotoxic chemotherapy (cabazi-
taxel) [16], immunotherapy (sipuleucel-T) [17], radionu-
clides (radium-223) [18], novel androgen blockade
(MDV3100) [19-21], and cellular pathway targeting
drugs (cabozantinib) [22]. However, ahead of all of these
in the development process has been abiraterone acetate
(Zytiga: Janssen Pharmaceuticals). HT eventually fails for
most men, even though they have castrate levels of cir-
culating androgens. This is called castration-refractory
prostate cancer (CRPC). Recent evidence suggests the
failure is due to persistent activity of the androgen re-
ceptor, occurring because of intracellular conversion of
steroids precursors to androgenic steroids by prostate
cancer cells. A key enzyme in this process is CYP17, an
enzyme which represents a logical target for therapy in
later stages of prostate cancer [23]. Abiraterone is a se-
lective inhibitor of CYP17 and is highly active in patients
developing resistance to standard androgen ablation
therapies [24-26]. First results of a phase III study com-
paring abiraterone to placebo in CRPC patients follow-
ing chemotherapy with docetaxel reported an absolute
improvement in overall survival of more than 4 months,
hazard ratio 0.65 (95% CI, 0.54 to −0.77) [27]. The drug
received marketing authorization in European Union
from September 2011 and there is a robust biological hy-
pothesis [28]. The TMG hypothesized that abiraterone
could have a greater absolute effect when given to men
with high-risk disease starting long-term HT (that is,
earlier in the time course of the disease and synchron-
ously with standard androgen ablation).
Design issues
The addition of HT plus abiraterone means that STAM-
PEDE has become a five-arm trial from mid-November
2011. The design parameters for STAMPEDE in Table 1
relate to each pairwise comparison of research arm
against control arm. The same parameters and targets
for the new comparison of abiraterone versus control
have been chosen; these will only be made within con-
temporaneously recruited patients. That is, patients allo-
cated to a new research arm are compared against
control arm patients randomized after a new research
arm was added.
Inevitably, analyses of new comparisons will be later
than for the original comparisons. It is anticipated that
completing accrual to the new research comparison (and
possibly further additional arms) may occur before the
primary survival results from the initial comparisons are
known.
The key question was how many patients are required
to attain these parameters? This depends on traditional
and MAMS-specific factors, including recruitment rate,
power and significance level for each stage. We realized
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parison would quickly be activated in many sites. Fur-
thermore, accrual to the new comparison would be
boosted when recruitment to the original research arms
stopped. A survey of participating sites (unpublished)
suggested that overall accrual could even be boosted by
including an ‘attractive’ new research arm. Accrual rates
have increased throughout the trial (Figure 2) and could
continue to increase regardless of the addition of a new
arm.
For the sample size calculations, this comparison was
first treated as if it were a two-arm multi-stage trial
using nstage [8,9] to obtain the control arm events
required to trigger the end of each stage. The duration
of the trial was then estimated using ARTPEP [10] to es-
timate when these events would be attained. ARTPEP
offers much flexibility in accrual rates, follow-up dur-
ation and loss-to-follow-up.
Figure 3 (left) shows projected cumulative accrual to
the new comparison (not the full trial) in the basic sce-
nario. A boost to the accrual rate for the comparison is
seen when the original research arms complete accrual,Control = 746 pts
Research = 746 pts
Total = 1492 pts
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follow-up period, the length of co-recruitment with the
original arms and the median FFS and overall survival
times, as well as introducing one or two further research
arms later in the trial.
Accrual to this comparison is planned to stop at the
sooner of (i) 1,500 new patients allocated to control or
abiraterone or (ii) three years after activating the abira-
terone comparison. The comparison should mature in
around five years, depending on the mix of metastatic
and non-metastatic patients joining the trial. Import-
antly, accrual to this comparison should complete before
the original comparisons mature for the definitive pri-
mary outcome measure.
Practical experience
The abiraterone comparison was formally launched on
Tuesday 15 November 2011. A total of 31 patients
joined STAMPEDE by the end of the first full week, with
18 allocated to arms A or G (around the 4 of 7
expected). We describe the steps that we took to reach
this point.
Janssen’s first formal results for abiraterone in late-
stage prostate cancer were published in April 2011 [27]
and updated at the American Society of Clinical Oncol-
ogy (ASCO) 2011 [29], with abiraterone being licensed
in Europe in September 2011. Discussions between the
TMG and Janssen were formally initiated much earlier
in March 2010 with an application by the trial team for
an investigator-initiated study. In July 2010, the main
funding body, Cancer Research United Kingdom, orga-
nized a scientific peer review of the revised trial applica-
tion to conditionally amend STAMPEDE pending
successful negotiations and a successful results from the
Janssen’s COU-AA-301 trial. This included findings
reflecting broad enthusiasm among investigators and
patients to assess abiraterone, plus the TMG’s enthusi-
asm for this new approach.
Subsequent months were spent discussing the dose
and duration of abiraterone, steroid support, details of
drug supply and distribution, safety reporting, research
supports and contracts with Janssen’s United Kingdom,
European and Global affiliates. The sample size esti-
mates were then finalized and the protocol was condi-
tionally updated.
The principle of adding a new arm was discussed at
each IDMC and TSC meeting in 2010 and 2011. The
TSC reviewed the protocol in August 2011. The new re-
search arm G (hormone therapy plus abiraterone) was
then submitted to the regulatory agency and ethics com-
mittee late in August 2011 as a substantial protocol
amendment (version 8.0) along with an updated PIS.
This updated protocol included some modified eligibility
criteria pertinent to assessing abiraterone. All patientsnow needed histological confirmation of prostate cancer,
something not previously required for the subset of
patients with bone metastases and PSA>100 ng/ml. In
the United Kingdom this affected only a small propor-
tion of patients and fitted in with current National Insti-
tute for Health and Clinical Excellence (NICE) guidance
recommending a biopsy where a patient may wish to
enter a trial. This is also consistent with most trials of
new agents in prostate cancer. Further clarifications on
liver and renal function that are associated with fitness
for abiraterone were also introduced but were unlikely
to markedly affect the number of eligible patients.
The TMG also introduced an unrelated change for
non-metastatic patients following recent results from
SPCG-7 [30] and MRC PR07/NCIC PR.3 [31], which
demonstrated a survival advantage to HT plus radiother-
apy over HT alone in men with locally advanced, non-
metastatic prostate cancer. Previously, radiotherapy
had been encouraged for such men in STAMPEDE, but
the trial has been updated to reflect the new standard-
of-care.
The likely addition of abiraterone had been extensively
promoted at conferences and investigator meetings in
addition to the survey. The trial team started training
participating sites in parallel with the contractual and
regulatory processes. Regional launch and training meet-
ings in Glasgow, London, Cardiff and Manchester in
September 2011 and October 2011 were supplemented
with teleconferences. This included making clear that
there would be a formal switchover date to protocol ver-
sion 8.0 and that centers would need new local approval
to maintain accrual beyond this date. That is, all sites
needed to provide evidence to be given permission to
start randomizing again.
The ethics committee responded quickly and positively
in September 2011, the regulatory agency gave approval
in October 2011 within their 35-day window, and nei-
ther body requested changes.
The chosen date for the switchover was 15 November
2011, allowing sites 35 days from 12 October 2011 to at-
tain local approvals. Figure 4 shows sites with local
approvals for v8.0 over time. The first site gained ap-
proval within one week demonstrating the feasibility of
quick amendments. By the time of final activation 83 of
104 sites had the necessary permissions in place. This
denominator includes some sites that had not previously
participated and were waiting for this protocol amend-
ment. Four-fifths were ready within five weeks. This
does not include centers in Switzerland, where the co-
ordinating body, the Swiss Group for Clinical Cancer
Research (Schweizerische Arbeitsgemeinschaft für Kli-
nische Krebsforschung or SAKK), chose not to submit
for approvals until after activation in the United King-
dom. All Swiss sites suspended accrual. Sites that were
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department, one where the PI had recently changed and
one with unrelated pharmacy problems. The trial team
ensured that all sites with approvals prior to switchover
had access to abiraterone on-site from the day of
activation.
It is unlikely that any completely new trial could have
83 sites ready to recruit on activation day, something
that would be a considerable achievement. Figure 2
shows (on the left axis) the number of sites recruiting
their first patient to the trial, demonstrating how long de
novo trials may take to activate sites. Site activation was
deliberately limited during the original Pilot Phase, but
new sites have continued to activate throughout, giving
accelerated recruitment rates. Therefore, a new, separate
trial of abiraterone would likely have taken much longer
to get to the same rate of recruitment as STAMPEDE
achieved immediately. The cost of a separate trial would
also have been higher if the trial took longer to conduct.
A separate trial would also potentially have become
established as a competing trial, with the possibility of
an adverse effect on recruitment to both trials. Combin-
ing the new comparison into STAMPEDE also brings
efficiencies in costs regarding site training, site monitor-
ing and database construction.
We anticipated that accrual would be ahead of the
switchover with sites that might want to wait until after
switchover to randomize new patients. However, in the
last full week prior to switchover 18 patients were ran-
domized and 4 further patients were randomized the daybefore switchover. On the day of activation, 15 Novem-
ber 2011, 6 patients were randomized and by the end of
January 2011, 53 patients were allocated to arm G.
Figure 5 summarizes the current design of the trial and
projected timelines.
Other issues
Randomization is achieved through minimization with a
random element [32,33] where 80% patients are allo-
cated to a minimizing arm across a series of clinically-
relevant stratification factors [7]. Therefore, at any
moment in time, the groups allocated to each arm are
well-balanced. After consideration, the TMG wiped the
stratification tables clean when the new comparison was
activated, effectively starting over again.
The possibility of the original research arms maturing
while the new comparison was ongoing was discussed.
Such data can be considered as if they are data emerging
from an external trial. Indeed, there are some other trials
which overlap partially with STAMPEDE in terms of
both population and treatment. The trial team would
react if change is needed, as demonstrated by the intro-
duction of radiotherapy in non-metastatic disease.
The future
The STAMPEDE investigators appreciate that challen-
ging and novel changes can only be made by working
with enthusiastic researchers. The group has, therefore,
encouraged discussions with sites from the outset and
has repeatedly engaged sites to ensure clinician and
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
A
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ADT + docetaxelC
ADT + celecoxibD
ADT + zoledronic acid + docetaxelE
ADT + zoledronic acid + celecoxibF
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ADT-alone
Past accrual
Possible future accrual
Follow-up
Figure 5 Trial arms open to allocat ion and fur ther t imelines as of Nov 2011.
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http://www.trialsjournal.com/content/13/1/168patient input and ‘buy-in’. The potential changes have
been presented in newsletters and at regional meetings
over a long period. Furthermore, researchers have been
encouraged to bring forward ideas for further arms that
might be worthy of assessment in this trial population.
Indeed, the STAMPEDE TMG has started to consider
further arms. In September 2011 the TMG prioritized
potential questions. Any new comparison would take at
least one year to develop and activate so it is important
that such discussions start early if they are to be acti-
vated. Champions for potential new agents have been
making contact with potential industry partners al-
though the most favored question was radiotherapy for
metastatic disease, which pertains only to a subgroup of
patients. This provides a further challenge for our flex-
ible design to address. Projections for various recruit-
ment scenarios demonstrate that this could be achieved
if participating centers are keen to formulate questions
together. A questionnaire was distributed to sites in No-
vember 2011 and the concept was received positively.
This has been approved by the trial committees and has
been successfully peer-reviewed by Cancer Research
United Kingdom. A formal amendment to activate this
comparison will be developed during summer 2012. We
estimated that undertaking this comparison within
STAMPEDE would cost only about 60% as much as a
separate stand-alone trial.
Conclusions
STAMPEDE is a high-profile adaptive randomized con-
trolled trial (RCT). We believe the merits in this flexible
approach are clearly apparent, and we encourage others
to implement this or similar designs in other settings. Inparticular, the considerable costs associated with trial
start up and close down can be substantially reduced by
evaluating many new treatments simultaneously and also
by using intermediate analyses to run a seamless phase
II/III approach [3]. The ability to rapidly add new arms
is also an important innovation. We have essentially set
up a new phase III comparison of abiraterone in 100
centers in 18 months from the first idea to first patient;
From protocol sign-off to opening was less than 4
months. The price in trial administration costs (ignoring
drug associated costs which accrue whatever route one
chooses) ran into tens of thousands of pounds sterling
rather than the much larger sums normally associated
with trial set up on this scale de novo. Experience shows
that funders, regulators, investigators and, most import-
antly, patients can deal with the complex issues involved.
Indeed, as the trial has progressed, companies wishing to
have their drug included within the trial have started to
approach us.
We hope that this very positive experience of an adap-
tive trial will encourage others to undertake further trials
like STAMPEDE and that our experience will smooth
the passage of further such trials.
In summary, the STAMPEDE trial has confirmed the
notion that MAMS trials speed the evaluation of new
treatments by testing many treatments simultaneously
and by using lack-of-benefit analyses to focus research
efforts towards the more promising research arms. It has
also demonstrated that accrual and treatment of insuffi-
ciently active arms can be stopped successfully without
this radical change affecting the continued evaluation of
agents still undergoing testing in this setting. Finally,
and importantly, we have demonstrated that adding
Sydes et al. Trials 2012, 13:168 Page 12 of 14
http://www.trialsjournal.com/content/13/1/168additional research arms to enable new and rapid com-
parisons of novel agents either alone or in combination
is possible, and that the modification of a complex
protocol to accommodate changes in practice during the
running of a MAMS study is achievable. This is particu-
larly important in an ongoing trial of this type. We have
shown that a major change to the protocol can be swiftly
and effectively achieved in large numbers of centers, and
high volume recruitment can be continued in a seam-
less, safe and efficient manner.
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